Carcinogenesis and the hypothesis of phylogenetic reversion

Analytical and Quantitative Cytology and Histology

Volumn 28, Issue 5, 2006, Pages 243-252

  Bartels, Peter H ^a   Ranger Moore, James ^a   Alberts, David ^b   Hess, Lisa ^c   Scarpelli, Marina ^d   Montironi, Rodolfo ^d  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Carcinogenesis; Chemoprevention; Phylogenetic reversion; Redifferentiation

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CARCINOGENESIS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL GROWTH; CHEMOPROPHYLAXIS; CHROMATIN; CPG ISLAND; DNA METHYLATION; FEEDBACK SYSTEM; GENE EXPRESSION; GENE SILENCING; GENETIC EPIGENESIS; HETEROCHROMATIN; HUMAN; HUMAN CELL; HYPOTHESIS; INTERPHASE; KARYOMETRY; MALIGNANT TRANSFORMATION; MUTAGENESIS; PHYLOGENETIC REVERSION; PHYLOGENY; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HEALTH; HUMANS; MODELS, GENETIC; NEOPLASMS; PHYLOGENY;

EID: 33750283790     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Loeb LA: Mutator phenotype may be required for multistep carcinogenesis. Cancer Res 1991;12:3073-3079
2. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996;87:159-170
3. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;1:57-70
4. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Nakamura Y, White R: Genetic alterations during colorectal tumor development. N Engl J Med 1988;9:525-532
5. Hahn W, Counter C, Lundberg S, Beijersbergen R, Brooks M, Weinberg R: Creation of human tumor cells with defined genetic elements. Nature 1999;400:464-468
6. Renan MJ: How many mutations are required for tumorigenesis: Implications from human cancer data. Mol Carcinog 1993;7:139-146
7. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D: Genetic progression model for head and neck cancers implications for field cancerization. Cancer Res 1996;56:2488-2492
8. Sonnenschein C, Soto AM: Somatic mutation theory of carcinogenesis: Why it should be dropped and replaced. Mol Carcinog 2000;29:205-211
9. Sonnenschein C, Soto A: The society of cells: Cancer and control of cell proliferation. New York, Springer-Verlag, 1999
10. Wied GL, Bartels PH, Bibbo M, Sychra JJ: Cytomorphometric markers for uterine cancer in intermediate cells. Anal Quant Cytol Histol 1980;2:257-263
11. Bartels PH, Montironi R, Hamilton PW, Thompson D, Vaught L, Bartels HG: Nuclear chromatin texture in prostatic lesions: II. PIN and malignancy associated changes. Anal Quant Cytol Histol 1998;20:397-406
12. Montag AG, Bartels PH, Dytch HE, Lerma-Puertas E, Michelassi F, Bibbo M: Karyometric features in nuclei near colonic adenocarcinoma: Statistical analysis. Anal Quant Cytol Histol 1991;13:159-167
13. MacAulay C, Lam S, Payner PW, LeRiche HC, Palcic B: Malignancy associated changes in bronchial epithelial cells in biopsy specimens. Anal Quant Cytol Histol 1995;17:55-71
14. Susnik B, Worth A, LeRiche J, Palcic G: Malignancy associated changes in the breast: Changes in chromatin distribution in epithelial cells in normal appearing tissue adjacent to cancer. Anal Quant Cytol Histol 1995;17:62-68
15. Anderson N, Houghton J, Kirk SJ, Frank D, Ranger-Moore J, Alberts DS, Thompson D, Bartels PH: Malignancy-associated changes in lactiferous duct epithelium. Anal Quant Cytol Histol 2003;25:63-72
16. Rashevsky: Mathematical Biophysics. Chicago, University of Chicago Press, 1954
17. Egger G, Liang G, Aparicio A, Jones P: Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-463
18. Esteller M, Herman J: Cancer as an epigenetic disease: DNA methylation and chromatin laterations in human tumors. J Pathol 2002;196:1-7
19. Baylin S: Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin Cancer Biol 2002;12:331-337
20. Baylin S, Esteller M, Rountree M, Bachman K, Schuebel K, Herman J: Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-692
21. Stirzaker C, Song J, Davidson B, Clark S: Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 2004;64:3871-3877
22. Reik W, Dean W, Walter J: Epigenetic reprogramming in mammalian development. Science 2001;293:1089-1093
23. Teodoridis JM, Strathdee G, Brown R: Epigenetic silencing mediated by CpG island methylation: Potential as a therapeutic target and as a biomarker. Drug Resist Updat 2004;7:267-278
24. Brown R, Strathdee G: Epigenomics and epigenetic therapy of cancer. Trends Mol Med (Suppl 4) 2002;8:S43-S48
25. Marks PA, Miller T, Richon V: Histone deacetylases. Curr Opin Pharmacol 2003;3:344-351
26. Worm J, Guldberg P: DNA methylation: An epigenetic pathway to cancer and a promising target for anticancer therapy (review). J Oral Pathol Med 2002;13:443-449
27. Kinzler K, Vogelstein B: Landscaping the cancer terrains. Science 198;280:1036-1037
28. Olumi AR, Grossfeld GD, Hayword SW, Carroll PR, Tisty TD, Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999;59:5002-5011
29. Garcia F, Davis J, Alberts DS, Liu Y, Thompson D, Bartels P: A karyometric approach to the characterization of atypical endometrial hyperplasia with and without co-occurring adenocarcinoma. Anal Quant Cytol Histol 2003;25:339-346
30. Montironi R, Thompson D, Scarpelli M, Mazzucchelli R, Peketi P, Hamilton PW, Bostwick D, Bartels P: Karyometry detects subvisual differences in chromatin organization state between cribriform and flat high-grade prostatic intraepithelial neoplasia. Mod Pathol 2004;17:928-937
31. Pelengaris S, Khan M: The Molecular Biology of Cancer. Oxford, Blackwell, 2005
32. Stonier R, Yu X: Complex Systems: Mechanisms of Adaptation. Berlin, IOS Press, 1994
33. Weibull W: A statistical distribution function of wide applicability. J Appl Mechan 1951;18:293-297
34. Collett D: Modelling Survival Data in Medical Research. New York, CRC, 1994
35. Beaudet AL, Jiang Y: A rheostat model for rapid and reversible form of imprinting-dependent evolution. Am J Human Genet 2002;70:1389-1397
36. Wilson V, Jones P: DNA methylation decreases in aging but not in immortal cells. Science 1983;220:1055-1057
37. Richardson B: Role of DNA methylation in the regulation of cell function: Autoimmunity, aging, and cancer. J Nutr 2002;132:2401s-2405s
38. Ellis IO, Finder SE, Lee AH, Elston CW: A critical appraisal of existing classification systems of epithelial hyperplasia and in situ neoplasia of the breast with proposals for future methods of categorization: Where are we going? Semin Diagn Pathol 1999;16:202-208
39. da Silva V, Montironi R, Thompson D, Bartels HG, Vaught L, Hamilton PW, Bartels PH: Chromatin texture in high grade prostatic intraepithelial neoplasia and early invasive carcinoma. Anal Quant Cytol Histol 1999;21:113-120
40. Kittler R, Putz G, Pelletier L, Poser I, Heninger A, Drechsekl D, Fischer S, Konstantinova I, Habermann B, Garbner H, Yaspo M, Himmelbauer H, Korn B, Neugebauer I, Pisabarro M, Buchholz F: An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature 2004;432:1036-1040
41. Cheutin T, McNairn A, Jenuwein T, Gilbert D, Singh P, Misteli T: Maintenance of stable heterochromatin domains by dynamic HP1 binding. Science 2003;299:721-725
42. Harbers E, Sandritter W: Gesteigerte Heterchromatisierung als pathogenetisches Prinzip. Deutsche Med Wochenschrift 1968;93:269-271
43. Mintz B, Ilmensee K: Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci USA 1975;72:3585-3589
44. Ilmensee K, Mintz B: Totipotency and normal differentiation of single teratocarcinoma cell cloned by injection into blastocysts. Proc Natl Acad Sci USA 1976;73:549-553
45. Foulds L: The Experimental Study of Tumor Progression. London, Academic Press, 1954
46. Novell PC: The clonal evolution of tumor cell population. Science 1976;194:23-38
47. Armstrong WB, Taylor RH, Meyskens FL: Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of chemoprevention agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev 2003;12:589-592
48. Ranger-Moore J, Alberts DS, Montironi R, Garcia F, Davis J, Frank D, Brewer M, Mariuzzi G, Bartels H, Bartels P: Karyometry in the early detection and chemoprevention of intraepithelial lesions. Eur J Cancer 2005;41:1875-1888
49. Bartels PH, Ranger-Moore J, Stratton MS, Bozzo P, Einspahr J, Liu Y, Thompson D, Alberts DS: Statistical analysis of chemopreventive efficacy of vitamin A in sun-exposed, normal skin. Anal Quant Cytol Histol 2002;24:185-197
50. Bartels PH, Ranger-Moore J, Bartels HG, Alberts DS: Second order discriminant analysis in chemopreventive efficacy measurement. Anal Quant Cytol Histol 2005;27:15-26
51. Brewer MA, Ranger-Moore J, Greene MH, Alberts DS, Liu Y, Bartels HG, Baruch AC, Bartels PH: Preneoplastic changes in ovarian tissues. Anal Quant Cytol Histol 2004;26:207-216